New Investigational Therapy for Lupus Treatment, GLPG3667, Begins Phase 2 Study

A new investigational therapy, GLPG3667, for adults with active lupus is beginningPhase 2 study to examine the safety, tolerability and efficacy of the treatment. The therapy is a tyrosine kinase 2 or TYK2 enzyme inhibitor, which prevents inflammation. TYK2 is a critical driver of disease in lupus.

The GALACELA trial will enroll approximately 140 adults with lupus who will receive the treatment orally once per day or placebo for 32 weeks.

Continue to follow the Lupus Foundation of America for updates on GLPG3667 as well as other lupus clinical trials.

Read the announcement